Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.69 -1.12%

-$0.34 today

Market cap
$1.75B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.76M

Average 0.64M

STOK Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Stoke Therapeutics, Inc.NASDAQ: STOK

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow turns negative

Q1 FY2026 free cash flow was -$60.94M, compared with $131.68M a year earlier. Trailing-twelve-month free cash flow was -$147.7M.

Context

  • Free cash flow amounted to 24.4% of revenue in FY2025, down 213.8 pp from a year earlier.
  • Free cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly free cash flow holds near -$60.94M or moves back toward the trailing-twelve-month quarterly average of -$36.92M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$60.94M+98.6% QoQ
Last fiscal yearDec 2025
$44.92M+151.6% YoY
LTMMar 2026
-$147.7M-313.4% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-146.3%——
1 year+151.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
44.92M USD
Year-over-year change
+151.6%

Free Cash Flow vs competitors

How STOK compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -313.4% is the lowest of 6, against a peer median of +13.5%.
  • Free cash flow amounts to 460.4% of revenue for STOK, versus a peer median of 255.4%.
STOK Competitors
Free Cash Flow for STOK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$616.26M USD+103.6%+2.8%64.2%
BEAMBeam Therapeutics Inc.LTM Jun 2026$372.77M USD+4.8%+138.8%238.9%
WVEWave Life Sciences Ltd.LTM Mar 2026$183.34M USD+1.1%+13.2%255.4%
STOKStoke Therapeutics, Inc.LTM Mar 2026$147.7M USD-313.4%—460.4%
SLNSilence Therapeutics plcLTM Mar 2026$65.67M USD—+2.7%7126.6%
DSGNDesign Therapeutics, Inc.LTM Mar 2026$54.12M USD+13.5%+1.5%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€48.99M EUR+29.0%-9.3%364.5%
Peer median (excluding STOK) —+13.5%+2.7%255.4%

Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Depreciation & Amortization974K1.55M2.47M2.18M1.77M
Deferred Income Tax172K0000
Stock-Based Compensation16.45M22.85M25.26M27.47M32.24M
Change in Working Capital46K43.02M(6.03M)(28.14M)16.35M
Accounts Receivables0000(4.27M)
Inventory00000
Accounts Payables2.9M121K(3.21M)3.09M21.29M
Other Working Capital(2.85M)42.9M(2.82M)(31.23M)(675K)
Other Non-Cash Items1.26M1.78M1.94M623K2.12M
Operating Cash Flow(66.91M)(31.87M)(81.07M)(86.85M)45.59M
Capital Expenditures(1.2M)(3.96M)(1.62M)(203K)(670K)
Acquisitions (Net)75.23M45.34M000
Purchases of Investments(87.23M)(201.32M)0(167.27M)(322.72M)
Sales of Investments12M159.4M107.56M60M136.58M
Other Investing Activities(75.23M)(45.34M)000
Investing Cash Flow(76.43M)(45.88M)105.95M(107.48M)(186.81M)
Debt Repayment00000
Common Stock Issued1.29M45.34M52.08M128.84M97.39M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2K)1.07M926K2.25M0
Financing Cash Flow1.28M46.41M53.01M131.09M97.39M
Effect of Forex Changes00000
Net Change in Cash(142.05M)(31.34M)77.89M(63.23M)(43.84M)
Free Cash Flow(68.11M)(35.83M)(82.68M)(87.05M)44.92M

Stoke Therapeutics, Inc.

NASDAQ:STOK

Intrinsic Alpha fair value

Locked

Current Price

$26.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.